Bei Liu

Myeloid reprogramming generates myeloid-derived activating cells to potentiate radiotherapy and suppress metastasis.

These findings define MDACs as an immunogenic myeloid subset and establish myeloid reprogramming as a strategy to improve radiotherapy-immunotherapy outcomes.